Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major

BACKGROUND: Prospective data on cardiac iron removal are limited beyond one year and longer-term studies are, therefore, important. DESIGN AND METHODS: Seventy-one patients in the EPIC cardiac substudy elected to continue into the 3(rd) year, allowing cardiac iron removal to be analyzed over three y...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Pennell, Dudley J., Porter, John B., Cappellini, Maria Domenica, Chan, Lee Lee, El-Beshlawy, Amal, Aydinok, Yesim, Ibrahim, Hishamshah, Li, Chi-Kong, Viprakasit, Vip, Elalfy, Mohsen S., Kattamis, Antonis, Smith, Gillian, Habr, Dany, Domokos, Gabor, Roubert, Bernard, Taher, Ali
Formato: Artigo
Lenguaje:Inglês
Publicado: Ferrata Storti Foundation 2012
Materias:
Original Articles and Brief Reports
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3366648/
https://ncbi.nlm.nih.gov/pubmed/22271905
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2011.049957
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares